Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News

Mesoblast's Revascor Will Go Into Phase III in 2013 


December 12, 2012 - (Life Scientist) - "Mesoblast (ASX:MSB) shares are up 3.5% following news that its 19.4% shareholder Teva has confirmed it will go ahead with a phase III trial of heart failure treatment, Revascor, in 2013. In an investor briefing held by Teva in the United States there were several phase II and III trials that were slated to be discontinued, and Revascor was not among them." Read Full Article   


Posted on 20-Dec-12 by Toto, Brent
Tags: Science and Industry News
Trackback Url  |  Link to this post | Bookmark this post with: